Glen Kristiansen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9168040/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet Oncology, The, 2020, 21, 222-232.	5.1	364
2	CD24 Is Expressed in Ovarian Cancer and Is a New Independent Prognostic Marker of Patient Survival. American Journal of Pathology, 2002, 161, 1215-1221.	1.9	239
3	CD24 expression is a new prognostic marker in breast cancer. Clinical Cancer Research, 2003, 9, 4906-13.	3.2	213
4	Exome Sequencing Identifies Biallelic MSH3 Germline Mutations as a Recessive Subtype of Colorectal Adenomatous Polyposis. American Journal of Human Genetics, 2016, 99, 337-351.	2.6	198
5	The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. Clinical Cancer Research, 2016, 22, 1969-1977.	3.2	170
6	Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. Journal of Pathology, 2005, 205, 359-376.	2.1	162
7	ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate, 2003, 54, 34-43.	1.2	134
8	CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate, 2004, 58, 183-192.	1.2	122
9	Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling. Nature Medicine, 2018, 24, 463-473.	15.2	120
10	Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotype. Clinical Endocrinology, 2015, 83, 779-789.	1.2	115
11	Performance Evaluation of Kits for Bisulfite-Conversion of DNA from Tissues, Cell Lines, FFPE Tissues, Aspirates, Lavages, Effusions, Plasma, Serum, and Urine. PLoS ONE, 2014, 9, e93933.	1.1	110
12	Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. Modern Pathology, 2015, 28, 612-630.	2.9	106
13	The translational potential of microRNAs as biofluid markers of urological tumours. Nature Reviews Urology, 2016, 13, 734-752.	1.9	104
14	Novel insights into the function of <scp>CD24</scp> : A driving force in cancer. International Journal of Cancer, 2021, 148, 546-559.	2.3	100
15	Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study. Clinical Chemistry, 2017, 63, 1288-1296.	1.5	97
16	Quantification of Liver Fibrosis at T1 and T2 Mapping with Extracellular Volume Fraction MRI: Preclinical Results. Radiology, 2018, 288, 748-754.	3.6	96
17	High-accuracy prostate cancer pathology using deep learning. Nature Machine Intelligence, 2020, 2, 411-418.	8.3	89
18	Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma. Clinical Epigenetics, 2018, 10, 11.	1.8	87

#	Article	IF	CITATIONS
19	Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. Histopathology, 2016, 69, 441-449.	1.6	82
20	PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma. Oncotarget, 2017, 8, 52889-52900.	0.8	82
21	Analysis of TET Expression/Activity and 5mC Oxidation during Normal and Malignant Germ Cell Development. PLoS ONE, 2013, 8, e82881.	1.1	80
22	CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ TÂCells. Immunity, 2020, 53, 805-823.e15.	6.6	79
23	Diagnostic and prognostic molecular biomarkers for prostate cancer. Histopathology, 2012, 60, 125-141.	1.6	74
24	<i>PD-L1</i> promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncotarget, 2016, 7, 79943-79955.	0.8	73
25	CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 185-196.	1.4	71
26	Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role. Journal of Urology, 2018, 199, 370-377.	0.2	71
27	<i>LAG3</i> (<i>LAG-3</i> , <i>CD223</i>) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma. , 2020, 8, e000552.		70
28	KDM5C Is Overexpressed in Prostate Cancer and Is a Prognostic Marker for Prostate-Specific Antigen-Relapse Following Radical Prostatectomy. American Journal of Pathology, 2014, 184, 2430-2437.	1.9	69
29	The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours <i>in vitro</i> and <i>in vivo</i> . Journal of Cellular and Molecular Medicine, 2017, 21, 1300-1314.	1.6	69
30	Expression of the Cell Adhesion Molecule CD146/MCAM in Non-Small Cell Lung Cancer. Analytical Cellular Pathology, 2003, 25, 77-81.	2.1	68
31	Diagnostic and Prognostic Value of SHOX2 and SEPT9 DNA Methylation and Cytology in Benign, Paramalignant and Malignant Pleural Effusions. PLoS ONE, 2013, 8, e84225.	1.1	68
32	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. American Journal of Surgical Pathology, 2020, 44, e47-e65.	2.1	68
33	Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study. British Journal of Cancer, 2018, 118, 1217-1228.	2.9	66
34	The <i>N</i> ⁶ â€methyladenosine (m ⁶ A) erasers alkylation repair homologue 5 (ALKBH5) and fat mass and obesityâ€associated protein (FTO) are prognostic biomarkers in patients with clear cell renal carcinoma. BJU International, 2020, 125, 617-624.	1.3	65
35	Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis. Laboratory Investigation, 2010, 90, 1102-1116.	1.7	62
36	Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. BMC Clinical Pathology, 2014, 14, 10.	1.8	61

#	Article	IF	CITATIONS
37	Peroxisome Proliferator-Activated Receptor Î ³ Is Highly Expressed in Pancreatic Cancer and Is Associated With Shorter Overall Survival Times. Clinical Cancer Research, 2006, 12, 6444-6451.	3.2	54
38	BMP Inhibition in Seminomas Initiates Acquisition of Pluripotency via NODAL Signaling Resulting in Reprogramming to an Embryonal Carcinoma. PLoS Genetics, 2015, 11, e1005415.	1.5	54
39	Quantitative Analysis of Kallikrein 15 Gene Expression in Prostate Tissue. Journal of Urology, 2003, 169, 361-364.	0.2	53
40	Low-level <i>APC</i> mutational mosaicism is the underlying cause in a substantial fraction of unexplained colorectal adenomatous polyposis cases. Journal of Medical Genetics, 2016, 53, 172-179.	1.5	51
41	<i>PD-L1</i> (<i>CD274</i>) and <i>PD-L2</i> (<i>PDCD1LG2</i>) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas. Oncotarget, 2018, 9, 641-650.	0.8	50
42	Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma. Clinical Epigenetics, 2019, 11, 161.	1.8	49
43	A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatment. Oncotarget, 2016, 7, 74931-74946.	0.8	49
44	The cancer/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas. British Journal of Cancer, 2016, 115, 454-464.	2.9	48
45	Systematic Analysis of the Expression of the Mitochondrial ATP Synthase (Complex V) Subunits in Clear Cell Renal Cell Carcinoma. Translational Oncology, 2017, 10, 661-668.	1.7	48
46	SEPT9 and SHOX2 DNA methylation status and its utility in the diagnosis of colonic adenomas and colorectal adenocarcinomas. Clinical Epigenetics, 2016, 8, 100.	1.8	46
47	Identification and Validation of Potential New Biomarkers for Prostate Cancer Diagnosis and Prognosis Using 2D-DIGE and MS. BioMed Research International, 2015, 2015, 1-23.	0.9	44
48	<scp>P</scp> athogenic and targetable genetic alterations in 70 urachal adenocarcinomas. International Journal of Cancer, 2018, 143, 1764-1773.	2.3	44
49	Endogenous Myoglobin in Breast Cancer Is Hypoxia-inducible by Alternative Transcription and Functions to Impair Mitochondrial Activity. Journal of Biological Chemistry, 2011, 286, 43417-43428.	1.6	43
50	Promoter methylation of the immune checkpoint receptor <i>PD-1</i> (<i>PDCD1</i>) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. OncoImmunology, 2016, 5, e1221555.	2.1	43
51	5′-tRNA Halves are Dysregulated in Clear Cell Renal Cell Carcinoma. Journal of Urology, 2018, 199, 378-383.	0.2	43
52	Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists. Annals of Diagnostic Pathology, 2014, 18, 333-342.	0.6	41
53	PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies. Journal of Molecular Diagnostics, 2017, 19, 107-114.	1.2	41
54	Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy. Breast Cancer Research and Treatment, 2018, 169, 447-455.	1.1	41

#	Article	IF	CITATIONS
55	Intraductal carcinoma of the prostate: a critical re-appraisal. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 525-534.	1.4	40
56	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. American Journal of Surgical Pathology, 2020, 44, e15-e29.	2.1	40
57	Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with <i>SLC45A3â€ERG</i> gene rearrangement and an unfavorable clinical course. International Journal of Cancer, 2013, 132, 807-812.	2.3	39
58	TRPM4 protein expression in prostate cancer: a novel tissue biomarker associated with risk of biochemical recurrence following radical prostatectomy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 345-355.	1.4	39
59	Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients. Clinical Epigenetics, 2017, 9, 125.	1.8	38
60	Report From the International Society of Urological Pathology (ISUP) Consultation Conference On Molecular Pathology Of Urogenital Cancers. II. Molecular Pathology of Bladder Cancer. American Journal of Surgical Pathology, 2020, 44, e30-e46.	2.1	38
61	Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma. EBioMedicine, 2020, 52, 102647.	2.7	38
62	Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of <i>miR-375</i> in prostate cancer progression. Oncotarget, 2016, 7, 59589-59603.	0.8	38
63	<i>PDCD1</i> (<i>PD-1</i>) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients. Oncotarget, 2017, 8, 41011-41020.	0.8	38
64	Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology. Oncotarget, 2017, 8, 92890-92903.	0.8	38
65	<i>CXCL12</i> promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients. Oncotarget, 2016, 7, 53309-53320.	0.8	37
66	<i>CDO1</i> promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients. Epigenetics, 2016, 11, 871-880.	1.3	37
67	<scp>UICC</scp> drops the ball in the 8th edition <scp>TNM</scp> staging of urological cancers. Histopathology, 2017, 71, 5-11.	1.6	37
68	Combination of CCl ₄ with alcoholic and metabolic injuries mimics human liver fibrosis. American Journal of Physiology - Renal Physiology, 2019, 317, G182-G194.	1.6	37
69	Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages. Urologia Internationalis, 2021, 105, 169-180.	0.6	37
70	SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells. Molecular Cancer Research, 2016, 14, 574-585.	1.5	36
71	Utility of Pathology Imagebase for standardisation of prostate cancer grading. Histopathology, 2018, 73, 8-18.	1.6	36
72	Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype. Human Pathology, 2018, 80, 55-64.	1.1	36

#	Article	IF	CITATIONS
73	Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA. International Journal of Molecular Sciences, 2017, 18, 1151.	1.8	35
74	Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma. Histopathology, 2019, 75, 865-875.	1.6	35
75	Low BUB1 expression is an adverse prognostic marker in gastric adenocarcinoma. Oncotarget, 2017, 8, 76329-76339.	0.8	34
76	Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites. Clinical Epigenetics, 2016, 8, 24.	1.8	31
77	Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging. Oncotarget, 2019, 10, 4149-4160.	0.8	31
78	Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma. EBioMedicine, 2020, 59, 102962.	2.7	31
79	Intraductal carcinoma of prostate reporting practice: a survey of expert European uropathologists. Journal of Clinical Pathology, 2016, 69, 852-857.	1.0	29
80	Contemporary prognostic indicators for prostate cancer incorporating International Society of Urological Pathology recommendations. Pathology, 2018, 50, 60-73.	0.3	29
81	Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded. Pathology, 2020, 52, 192-196.	0.3	29
82	The Distinct Gene Regulatory Network of Myoglobin in Prostate and Breast Cancer. PLoS ONE, 2015, 10, e0142662.	1.1	29
83	Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 ?g/L: Are they useful tools for early detection and screening of prostate cancer?. International Journal of Cancer, 2001, 93, 759-765.	2.3	28
84	Unique and redundant roles of SOX2 and SOX17 in regulating the germ cell tumor fate. International Journal of Cancer, 2020, 146, 1592-1605.	2.3	28
85	Hypoxia-inducible factor prolyl hydroxylase 2 (PHD2) is a direct regulator of epidermal growth factor receptor (EGFR) signaling in breast cancer. Oncotarget, 2017, 8, 9885-9898.	0.8	27
86	The Different Immune Profiles of Normal Colonic Mucosa in Cancer-Free Lynch Syndrome Carriers and Lynch Syndrome Colorectal Cancer Patients. Gastroenterology, 2022, 162, 907-919.e10.	0.6	27
87	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. American Journal of Surgical Pathology, 2020, 44, e66-e79.	2.1	26
88	Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. Clinical Epigenetics, 2020, 12, 94.	1.8	26
89	Systematic expression analysis of the mitochondrial complex III subunits identifies UQCRC1 as biomarker in clear cell renal cell carcinoma. Oncotarget, 2016, 7, 86490-86499.	0.8	26
90	Bi-allelic loss-of-function variants in <i>KIF21A</i> cause severe fetal akinesia with arthrogryposis multiplex. Journal of Medical Genetics, 2023, 60, 48-56.	1.5	26

#	Article	IF	CITATIONS
91	YRNA expression predicts survival in bladder cancer patients. BMC Cancer, 2017, 17, 749.	1.1	25
92	tRNA-halves are prognostic biomarkers for patients with prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 503.e1-503.e7.	0.8	25
93	CD10 Expression in Non-Small Cell Lung Cancer. Analytical Cellular Pathology, 2002, 24, 41-46.	2.1	24
94	Cultivation of Clear Cell Renal Cell Carcinoma Patient-Derived Organoids in an Air-Liquid Interface System as a Tool for Studying Individualized Therapy. Frontiers in Oncology, 2020, 10, 1775.	1.3	24
95	Systematic Expression Analysis of Mitochondrial Complex I Identifies NDUFS1 as a Biomarker in Clear-Cell Renal-Cell Carcinoma. Clinical Genitourinary Cancer, 2017, 15, e551-e562.	0.9	23
96	A randomized trial of riskâ€adapted screening for prostate cancer in young men—Results of the first screening round of the <scp>PROBASE</scp> trial. International Journal of Cancer, 2022, 150, 1861-1869.	2.3	23
97	Prognostic relevance of proliferation markers (Ki-67, PHH3) within the cross-relation of ERG translocation and androgen receptor expression in prostate cancer. Pathology, 2015, 47, 629-636.	0.3	22
98	Fibroblast growth factor receptor 1 gene amplification in gastric adenocarcinoma. Human Pathology, 2015, 46, 1488-1495.	1.1	22
99	Reporting intraductal carcinoma of the prostate: a plea for greater standardization. Histopathology, 2017, 70, 504-507.	1.6	22
100	DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients' survival, immune cell infiltrates, mutational load, and interferon γ signature. EBioMedicine, 2019, 48, 341-352.	2.7	22
101	Apelin and apelin receptor expression in renal cell carcinoma. British Journal of Cancer, 2019, 120, 633-639.	2.9	22
102	Mitochondrial PIWI-interacting RNAs are novel biomarkers for clear cell renal cell carcinoma. World Journal of Urology, 2019, 37, 1639-1647.	1.2	22
103	Comparative genomic profiling of glandular bladder tumours. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 445-454.	1.4	22
104	CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab). Cancer Immunology, Immunotherapy, 2021, 70, 1781-1788.	2.0	22
105	Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancer. International Journal of Cancer, 2017, 141, 1643-1653.	2.3	21
106	Threeâ€dimensional reconstruction of prostate cancer architecture with serial immunohistochemical sections: hallmarks of tumour growth, tumour compartmentalisation, and implications for grading and heterogeneity. Histopathology, 2018, 72, 1051-1059.	1.6	21
107	DNA Methylation Analysis of Free-Circulating DNA in Body Fluids. Methods in Molecular Biology, 2018, 1708, 621-641.	0.4	21
108	MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy. Oncotarget, 2017, 8, 14719-14735.	0.8	21

#	Article	IF	CITATIONS
109	Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted grading. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 777-786.	1.4	20
110	The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension. Oncotarget, 2018, 9, 36220-36237.	0.8	20
111	Pathology Imagebase—a reference image database for standardization of pathology. Histopathology, 2017, 71, 677-685.	1.6	19
112	Detailed analysis of adenosine A2a receptor (<i>ADORA2A</i>) and CD73 (5′-nucleotidase,) Tj ETQq0 0 0 rgBT Oncolmmunology, 2018, 7, e1452579.	/Overlock 2.1	10 Tf 50 62 19
113	Dataset for the reporting of prostate carcinoma in radical prostatectomy specimens: updated recommendations from the International Collaboration on Cancer Reporting. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 263-277.	1.4	19
114	Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral resection and enucleation specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR). Pathology, 2019, 51, 11-20.	0.3	19
115	Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II – Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy, Urologia Internationalis, 2021, 105, 181-191.	0.6	19
116	Adipophilin as prognostic biomarker in clear cell renal cell carcinoma. Oncotarget, 2017, 8, 28672-28682.	0.8	19
117	Interâ€observer agreement for the histological diagnosis of invasive lobular breast carcinoma. Journal of Pathology: Clinical Research, 2022, 8, 191-205.	1.3	19
118	Loss of Anterior Gradient-2 expression is an independent prognostic factor in colorectal carcinomas. European Journal of Cancer, 2014, 50, 1722-1730.	1.3	18
119	YRNA Expression Profiles are Altered in Clear Cell Renal Cell Carcinoma. European Urology Focus, 2018, 4, 260-266.	1.6	18
120	CircEHD2, CircNETO2 and CircEGLN3 as Diagnostic and Prognostic Biomarkers for Patients with Renal Cell Carcinoma. Cancers, 2021, 13, 2177.	1.7	18
121	Bisulfite Conversion of DNA from Tissues, Cell Lines, Buffy Coat, FFPE Tissues, Microdissected Cells, Swabs, Sputum, Aspirates, Lavages, Effusions, Plasma, Serum, and Urine. Methods in Molecular Biology, 2015, 1589, 139-159.	0.4	17
122	YRNA expression in prostate cancer patients: diagnostic and prognostic implications. World Journal of Urology, 2018, 36, 1073-1078.	1.2	17
123	Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study. Clinical Chemistry, 2019, 65, 559-568.	1.5	17
124	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers V. American Journal of Surgical Pathology, 2020, 44, e80-e86.	2.1	17
125	Membranous CD24 expression as detected by the monoclonal antibody SWA11 is a prognostic marker in non-small cell lung cancer patients. BMC Clinical Pathology, 2015, 15, 19.	1.8	16
126	PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy. Clinical Epigenetics, 2016, 8, 104.	1.8	16

#	Article	IF	CITATIONS
127	Prognostic role of TSPAN1, KIAA1324 and ESRP1 in prostate cancer. Apmis, 2021, 129, 204-212.	0.9	16
128	Evaluation of Global Histone Acetylation Levels in Bladder Cancer Patients. Anticancer Research, 2016, 36, 3961-4.	0.5	16
129	Hypoxia-inducible factor-mediated induction of WISP-2 contributes to attenuated progression of breast cancer. Hypoxia (Auckland, N Z), 2014, 2, 23.	1.9	15
130	Treatment Response Monitoring in Patients with Advanced Malignancies Using Cell-Free SHOX2 and SEPT9 DNA Methylation in Blood. Journal of Molecular Diagnostics, 2020, 22, 920-933.	1.2	15
131	Myoglobin, expressed in brown adipose tissue of mice, regulates the content and activity of mitochondria and lipid droplets. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2021, 1866, 159026.	1.2	14
132	CD57 Expression in Incidental, Clinically Manifest, and Metastatic Carcinoma of the Prostate. BioMed Research International, 2014, 2014, 1-9.	0.9	13
133	PITX3 DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma. Clinical Epigenetics, 2017, 9, 12.	1.8	13
134	Co-staining of microRNAs and their target proteins by miRNA in situ hybridization and immunohistofluorescence on prostate cancer tissue microarrays. Laboratory Investigation, 2019, 99, 1527-1534.	1.7	13
135	Integrative clinical transcriptome analysis reveals <i>TMPRSS2â€ERG</i> dependency of prognostic biomarkers in prostate adenocarcinoma. International Journal of Cancer, 2020, 146, 2036-2046.	2.3	13
136	Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours. Nuklearmedizin - NuclearMedicine, 2021, 60, 344-354.	0.3	13
137	The role of myoglobin in epithelial cancers: Insights from transcriptomics. International Journal of Molecular Medicine, 2020, 45, 385-400.	1.8	13
138	Increased IgG4â€positive plasma cells in nodularâ€sclerosing Hodgkin lymphoma: a diagnostic pitfall. Histopathology, 2020, 76, 244-250.	1.6	12
139	Novel insights into the mixed germ cell-sex cord stromal tumor of the testis: detection of chromosomal aneuploidy and further morphological evidence supporting the neoplastic nature of the germ cell component. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 615-623.	1.4	12
140	Ectopic Myoglobin Expression Is Associated with a Favourable Outcome in Head and Neck Squamous Cell Carcinoma Patients. Anticancer Research, 2016, 36, 6235-6242.	0.5	12
141	Significance of PITX2 Promoter Methylation in Colorectal Carcinoma Prognosis. Clinical Colorectal Cancer, 2018, 17, e385-e393.	1.0	10
142	TGR(mREN2)27 rats develop non-alcoholic fatty liver disease-associated portal hypertension responsive to modulations of Janus-kinase 2 and Mas receptor. Scientific Reports, 2019, 9, 11598.	1.6	10
143	Management of Capsular Contracture in Cases of Silicone Gel Breast Implant Rupture with Use of Pulse Lavage and Open Capsulotomy. Aesthetic Plastic Surgery, 2019, 43, 1173-1185.	0.5	10
144	Classic bladder exstrophy and adenocarcinoma of the bladder: Methylome analysis provide no evidence for underlying disease-mechanisms of this association. Cancer Genetics, 2019, 235-236, 18-20.	0.2	10

#	Article	IF	CITATIONS
145	Systematic expression analysis of the mitochondrial respiratory chain protein subunits identifiesCOX5Bas a prognostic marker in clear cell renal cell carcinoma. International Journal of Urology, 2019, 26, 910-916.	0.5	10
146	Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma. Clinical Genitourinary Cancer, 2019, 17, e167-e175.	0.9	10
147	Identification of miR-21-5p and miR-210-3p serum levels as biomarkers for patients with papillary renal cell carcinoma: a multicenter analysis. Translational Andrology and Urology, 2020, 9, 1314-1322.	0.6	10
148	Targeting glycolysis with 2-deoxy-d-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2255-2265.	1.2	10
149	Antibody selection influences the detection of AR-V7 in primary prostate cancer. Cancer Treatment and Research Communications, 2020, 24, 100186.	0.7	10
150	The signal transducer CD24 suppresses the germ cell program and promotes an ectodermal rather than mesodermal cell fate in embryonal carcinomas. Molecular Oncology, 2022, 16, 982-1008.	2.1	10
151	Manual Microdissection. Methods in Molecular Biology, 2009, 576, 31-38.	0.4	10
152	Loss of cadherin related family member 5 (CDHR5) expression in clear cell renal cell carcinoma is a prognostic marker of disease progression. Oncotarget, 2017, 8, 75076-75086.	0.8	10
153	Oxygen supply maps for hypoxic microenvironment visualization in prostate cancer. Journal of Pathology Informatics, 2016, 7, 3.	0.8	10
154	Is highâ€grade prostatic intraepithelial neoplasia (HGPIN) a reliable precursor for prostate carcinoma? Implications for clonal evolution and early detection strategies. Journal of Pathology, 2018, 244, 389-393.	2.1	9
155	Hereditary Diffuse Gastric Cancer: A Comparative Cohort Study According to Pathogenic Variant Status. Cancers, 2020, 12, 3726.	1.7	9
156	Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial). Journal of Cancer Research and Clinical Oncology, 2021, 147, 235-242.	1.2	9
157	Diagnostic accuracy of [99mTc]Tc-Sestamibi in the assessment of thyroid nodules. Oncotarget, 2017, 8, 94681-94691.	0.8	9
158	Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?. International Journal of Molecular Sciences, 2017, 18, 2023.	1.8	8
159	Downstream neighbor of SON (DONSON) is associated with unfavorable survival across diverse cancers with oncogenic properties in clear cell renal cell carcinoma. Translational Oncology, 2020, 13, 100844.	1.7	8
160	Systematic expression analysis of m 6 A RNA methyltransferases in clear cell renal cell carcinoma. BJUI Compass, 2021, 2, 402-411.	0.7	8
161	DNA Methylation of PITX2 and PANCR Is Prognostic for Overall Survival in Patients with Resected Adenocarcinomas of the Biliary Tract. PLoS ONE, 2016, 11, e0165769.	1.1	8
162	Handling and reporting of pelvic lymphadenectomy specimens in prostate and bladder cancer: a webâ€based survey by the European Network of Uropathology. Histopathology, 2019, 74, 844-852.	1.6	7

#	Article	IF	CITATIONS
163	Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy. Frontiers in Oncology, 2019, 9, 403.	1.3	7
164	Downstream Neighbor of SON (DONSON) Expression Is Enhanced in Phenotypically Aggressive Prostate Cancers. Cancers, 2020, 12, 3439.	1.7	7
165	Short-Term Western Diet Aggravates Non-Alcoholic Fatty Liver Disease (NAFLD) With Portal Hypertension in TGR(mREN2)27 Rats. International Journal of Molecular Sciences, 2020, 21, 3308.	1.8	7
166	DNA Promoter Methylation and ERG Regulate the Expression of CD24 in Prostate Cancer. American Journal of Pathology, 2021, 191, 618-630.	1.9	7
167	Extrahepatic Surgery in Cirrhosis Significantly Increases Portal Pressure in Preclinical Animal Models. Frontiers in Physiology, 2021, 12, 720898.	1.3	7
168	Correlation between enhancement characteristics of MR mammography and capillary density of breast lesions. European Journal of Radiology, 2014, 83, 2129-2136.	1.2	6
169	Exome sequencing characterizes the somatic mutation spectrum of early serrated lesions in a patient with serrated polyposis syndrome (SPS). Hereditary Cancer in Clinical Practice, 2017, 15, 22.	0.6	6
170	Comprehensive Analysis of the ATP-binding Cassette Subfamily B Across Renal Cancers Identifies ABCB8 Overexpression in Phenotypically Aggressive Clear Cell Renal Cell Carcinoma. European Urology Focus, 2020, 7, 1121-1129.	1.6	6
171	Otoferlin is a prognostic biomarker in patients with clear cell renal cell carcinoma: A systematic expression analysis. International Journal of Urology, 2021, 28, 424-431.	0.5	6
172	Clinical Studies on Cytokine-Induced Killer Cells: Lessons from Lymphoma Trials. Cancers, 2021, 13, 6007.	1.7	6
173	CD103+ Tissue Resident T-Lymphocytes Accumulate in Lung Metastases and Are Correlated with Poor Prognosis in ccRCC. Cancers, 2022, 14, 1541.	1.7	6
174	Comprehensive Analysis of N6-Methyladenosine (m6A) Writers, Erasers, and Readers in Cervical Cancer. International Journal of Molecular Sciences, 2022, 23, 7165.	1.8	6
175	A matched-pair analysis on survival and response rates between German and non-German cancer patients treated at a Comprehensive Cancer Center. BMC Cancer, 2019, 19, 1024.	1.1	5
176	Mitophagy-associated genes PINK1 and PARK2 are independent prognostic markers of survival in papillary renal cell carcinoma and associated with aggressive tumor behavior. Scientific Reports, 2020, 10, 18857.	1.6	5
177	miR-449a Repression Leads to Enhanced NOTCH Signaling in TMPRSS2:ERG Fusion Positive Prostate Cancer Cells. Cancers, 2021, 13, 964.	1.7	5
178	Comprehensive immunohistochemical analysis of N6-methyladenosine (m6A) writers, erasers, and readers in endometrial cancer. Journal of Cancer Research and Clinical Oncology, 2023, 149, 2417-2424.	1.2	5
179	Glutathione Sâ€ŧransferaseâ€pi protein expression in prostate cancer–not always a useful diagnostic tool. Histopathology, 2015, 67, 577-579.	1.6	4
180	Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System. Archives of Pathology and Laboratory Medicine, 2017, 141, 182-183.	1.2	4

#	Article	IF	CITATIONS
181	Cribriform and glomeruloid acinar adenocarcinoma of the prostate—an intratumoural intraductal carcinoma?. Histopathology, 2019, 74, 804-808.	1.6	4
182	The contrasting roles of Dysferlin during tumor progression in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 687.e1-687.e11.	0.8	4
183	Knockdown of Myoferlin Suppresses Migration and Invasion in Clear-Cell Renal-Cell Carcinoma. Anticancer Research, 2020, 40, 3119-3128.	0.5	4
184	Tumor Infiltrating Neutrophils Are Frequently Found in Adenocarcinomas of the Biliary Tract and Their Precursor Lesions with Possible Impact on Prognosis. Journal of Personalized Medicine, 2021, 11, 233.	1.1	4
185	Tissue Factor Expression Does Not Predict Mortality in Breast Cancer Patients. Anticancer Research, 2017, 37, 3259-3264.	0.5	4
186	Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial Cancer. Anticancer Research, 2022, 42, 1367-1376.	0.5	4
187	Reply: â€~A plea for greater standardization in intraductal carcinoma of the prostate —greater standardization requires greater evidence': let's use the available evidence. Histopathology, 2017, 70, 1013-1014.	1.6	3
188	No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in Germany. BMC Cancer, 2021, 21, 526.	1.1	3
189	Molecular pathology of Invasive Lobular Breast Carcinoma. Breast Disease, 2009, 30, 9-14.	0.4	2
190	High grade adenocarcinoma in the ectopic prostate accompanied by a low grade adenocarcinoma in the orthotopic prostate: an unusual diagnostic pitfall. Pathology, 2017, 49, 665-668.	0.3	2
191	Next-generation nuclear morphology to grade solid tumours. Lancet Oncology, The, 2018, 19, 275-277.	5.1	2
192	Chromosomal gains of 12p and 1q are not associated with inferior outcome of pediatric and adolescent germ cell tumors. Pediatric Blood and Cancer, 2019, 66, e27777.	0.8	2
193	High-grade Adenocarcinoma of the Prostate Mimicking Urothelial Carcinoma is Negative for TERT Mutations. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 523-528.	0.6	2
194	Rearranged ERG confers robustness to prostate cancer cells by subverting the function of p53. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 736.e1-736.e10.	0.8	2
195	The International Society of Urological Pathology Consultation on Molecular Pathology of Urogenital Cancer. American Journal of Surgical Pathology, 2020, 44, 859-861.	2.1	2
196	Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial. World Journal of Urology, 2021, 39, 65-72.	1.2	2
197	Overexpression of Parkin in clear cell renal cell carcinoma decreases tumor aggressiveness by regulating CKS2 levels. International Journal of Oncology, 2022, 60, .	1.4	2
198	Effect of Peripheral Artery Sympathetic Denervation on Muscle Microperfusion and Macroperfusion in an Animal Peripheral Artery Disease Model Using Contrast-Enhanced Ultrasound and Doppler Flow Measurement. Journal of Vascular and Interventional Radiology, 2015, 26, 1396-1402.e2.	0.2	1

#	Article	IF	CITATIONS
199	An overview of translational prostate cancer cohorts for prognostic and predictive studies. Histopathology, 2019, 74, 161-170.	1.6	1
200	Cardiac Myeloid Sarcoma: Multimodal Imaging and Histopathologic Findings. Radiology: Cardiothoracic Imaging, 2021, 3, e200540.	0.9	1
201	A Combined TLR7/TLR9/GATA3 Score Can Predict Prognosis in Biliary Tract Cancer. Diagnostics, 2021, 11, 1597.	1.3	1
202	CD3 and CD20 immune cell densities in primary tumors, lymph node metastasis, and recurrent disease samples of head and neck squamous cell carcinoma Journal of Clinical Oncology, 2020, 38, 6551-6551.	0.8	1
203	Is NF-κB predictive of biochemical recurrence in positive-margin prostate cancer?. Nature Reviews Urology, 2005, 2, 134-135.	1.4	0
204	Long-Term Analysis of Ab-2 (Clone SN3b) Immunoreactivity as a Prognostic Factor in Breast Carcinoma. Breast Care, 2015, 10, 273-276.	0.8	0
205	Detection of AR-V7 in primary prostate cancer. Cancer Treatment and Research Communications, 2020, 28, 100230.	0.7	0
206	Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten's to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial). Journal of Cancer Research and Clinical Oncology, 2021, 147, 1273-1274.	1.2	0
207	HGG-34. DETECTION OF ONCOGENIC FUSION EVENTS IN SUPRATENTORIAL GLIOBLASTOMAS OF YOUNG CHILDREN. Neuro-Oncology, 2020, 22, iii349-iii350.	0.6	0
208	Application of Computer Generated Images to train Pattern Recognition used in semiquantitative Immunohistochemistry Scoring. Apmis, 2021, , .	0.9	0
209	HGG-21. Oncogenic tyrosine kinase gene fusions in infant-type hemispheric gliomas - comparison of RNA- and DNA-based methods for their reliable detection. Neuro-Oncology, 2022, 24, i65-i65.	0.6	0